Upstream Bio, Inc./$UPB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Upstream Bio, Inc.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
- Ticker
- $UPB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 75
- Headquarters
- Waltham, United States
- Website
- upstreambio.com
UPB Metrics
BasicAdvanced
$177M
-
-$2.89
-
-
Price and volume
Market cap
$177M
52-week high
$33.68
52-week low
$2.68
Average daily volume
1.2M
Financial strength
Current ratio
27.994
Quick ratio
26.239
Long term debt to equity
0.001
Total debt to equity
0.004
Profitability
EBITDA (TTM)
-169.782
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-4,955.67%
Operating margin (TTM)
-5,382.65%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-30.28%
Return on equity (TTM)
-46.05%
Valuation
Price to revenue (TTM)
55.468
Price to book
0.65
Price to tangible book (TTM)
0.65
Price to free cash flow (TTM)
-1.284
Free cash flow yield (TTM)
-77.90%
Free cash flow per share (TTM)
-2.516
Growth
Revenue change (TTM)
15.98%
Earnings per share change (TTM)
-4.60%
UPB Financial Performance
Revenues and expenses
UPB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing UPB
Fund name | Fund size | $UPB weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.